NF2 and lung carcinoma: On the other hand, deep deletion and promoter methylation in LATS1/2, as well as inactivating mutations in NF2 are frequently reported in malignant mesotheliomas, gynaecologic and lung cancers, in congruence with their tumour-suppressive properties (Figure 2) [36,37,38,39,40,41,42].